



## Clinical trial results:

### A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF P-3073 FOR TOPICAL TREATMENT OF NAIL PSORIASIS

#### Summary

EudraCT number	2015-002365-34
Trial protocol	LV DE CZ PL BG GR
Global end of trial date	08 February 2017

#### Results information

Result version number	v1 (current)
This version publication date	20 February 2018
First version publication date	20 February 2018

#### Trial information

##### Trial identification

Sponsor protocol code	PM1434
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02606760
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Polichem S.A.
Sponsor organisation address	50, Val Fleuri Luxembourg, legally represented by branch in Lugano-Pazzallo, Switzerland, CH-6912
Public contact	Director, Clinical Development, Polichem S.A., +41 0919864024, maurizio.caserini@polichem.com
Scientific contact	Director, Clinical Development, Polichem S.A., +41 0919864024, maurizio.caserini@polichem.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 February 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 February 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this Phase III study was to evaluate the efficacy of P-3073 in the treatment of nail psoriasis.

Protection of trial subjects:

The clinical trial was conducted in compliance with globally accepted standards of good clinical practice (as defined in the ICH E6 guideline for good clinical practice, January 1997), in agreement with the Declaration of Helsinki for biomedical research in humans, revised version of Edinburgh (Scotland, 2000) including the Note of Clarification in paragraph 29, Washington (2002) and the announcements for the 'Principles for Correct Implementation of Clinical Trials'.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 November 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 124
Country: Number of subjects enrolled	Russian Federation: 27
Country: Number of subjects enrolled	Bulgaria: 64
Country: Number of subjects enrolled	Czech Republic: 67
Country: Number of subjects enrolled	Germany: 20
Country: Number of subjects enrolled	Latvia: 56
Worldwide total number of subjects	358
EEA total number of subjects	331

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	315
From 65 to 84 years	43
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted in Bulgaria, Czech Republic, Germany, Latvia, Poland and Russia between 23 November 2015 (first subject first visit) and 08 February 2017 (last subject last visit).

### Pre-assignment

Screening details:

A total of 378 subjects were enrolled and 358 subjects were randomised in the study and of them, 352 subjects were treated.

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	P-3073

Arm description:

Subjects with mild to moderate psoriatic fingernail/s, were treated with P-3073 nail solution as a topical application once daily for 24 weeks.

Arm type	Experimental
Investigational medicinal product name	P-3073
Investigational medicinal product code	
Other name	Calcipotriol
Pharmaceutical forms	Medicated nail lacquer
Routes of administration	Topical use

Dosage and administration details:

Subjects with mild to moderate psoriatic fingernail/s, were treated with P-3073 nail solution as a topical application once daily for 24 weeks.

<b>Arm title</b>	Vehicle
------------------	---------

Arm description:

Subjects with mild to moderate psoriatic fingernail/s, were treated with vehicle solution matched to P-3073 nail solution as a topical application once daily for 24 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	Vehicle
Pharmaceutical forms	Medicated nail lacquer
Routes of administration	Topical use

Dosage and administration details:

Subjects with mild to moderate psoriatic fingernail/s, were treated with vehicle solution matched to P-3073 nail solution as a topical application once daily for 24 weeks.

<b>Number of subjects in period 1</b>	P-3073	Vehicle
Started	181	177
Treated	176	176
Completed	158	155
Not completed	23	22
Consent withdrawn by subject	10	13
Adverse event, non-fatal	1	1
Pregnancy	1	1
Follow Up Visit Wrongly Not Performed	1	-
Lost to follow-up	7	3
Lack of efficacy	1	1
Protocol deviation	2	3

## Baseline characteristics

### Reporting groups

Reporting group title	P-3073
Reporting group description:	
Subjects with mild to moderate psoriatic fingernail/s, were treated with P-3073 nail solution as a topical application once daily for 24 weeks.	
Reporting group title	Vehicle
Reporting group description:	
Subjects with mild to moderate psoriatic fingernail/s, were treated with vehicle solution matched to P-3073 nail solution as a topical application once daily for 24 weeks.	

Reporting group values	P-3073	Vehicle	Total
Number of subjects	181	177	358
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	48.54	47.94	
standard deviation	± 13.32	± 13.45	-
Gender categorical			
Units: Subjects			
Female	72	63	135
Male	109	114	223
Nail Psoriasis Severity Index (NAPSI) Matrix Score			
Nail matrix psoriasis was assessed by the presence of any features including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail. The score was 0 if the findings were not present, 1 if they were present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail had a matrix score (0-4). The number of mild to moderate psoriasis fingernails analysed at the baseline visit are 1165 and 1166 for the reporting groups P-3073 and Vehicle respectively.			
Units: Score on a scale			
arithmetic mean	1.35	1.27	
standard deviation	± 1.04	± 1.06	-
Nail Psoriasis Severity Index (NAPSI) Bed Score			
Nail bed psoriasis was assessed by the presence of any features including onycholysis, oil drop (salmon patch) dyschromia, splinter hemorrhages, and nail bed hyperkeratosis in each quadrant of nail. The score was 0 if the findings were not present, 1 if they were present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail had a nail bed score(0-4). The number of mild to moderate psoriasis fingernails analysed at the baseline are 1165 and 1166 for P-3073 and Vehicle group, respectively			
Units: Score on a scale			
arithmetic mean	1.55	1.54	
standard deviation	± 0.98	± 0.94	-

## End points

### End points reporting groups

Reporting group title	P-3073
Reporting group description: Subjects with mild to moderate psoriatic fingernail/s, were treated with P-3073 nail solution as a topical application once daily for 24 weeks.	
Reporting group title	Vehicle
Reporting group description: Subjects with mild to moderate psoriatic fingernail/s, were treated with vehicle solution matched to P-3073 nail solution as a topical application once daily for 24 weeks.	
Subject analysis set title	Full Analysis Set (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: FAS consisted of all randomized subjects to whom the investigational drug was dispensed.	
Subject analysis set title	Safety analysis set (SAF)
Subject analysis set type	Safety analysis
Subject analysis set description: SAF consisted of all randomized subjects with at least one documented application of any study drug.	

### Primary: Change From Baseline in Total Nail Psoriasis Severity Index (NAPSI) Score at Week 24

End point title	Change From Baseline in Total Nail Psoriasis Severity Index (NAPSI) Score at Week 24
End point description: Nail psoriasis severity index (NAPSI) was used to assess nail psoriasis. The nail was assessed for nail matrix and bed psoriasis in each quadrant of the nail. The score was 0 if the findings were not present, 1 if they were present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail had a matrix score (0-4) and a nail bed score (0-4), and the total nail score was the sum of those two (0-8). The sum of the scores from all involved fingernails was 0-80 (total NAPSI score for that subject at that time). "n" signifies those subjects who were evaluable for this measure at given time point for each group.	
End point type	Primary
End point timeframe: Baseline, Week 24	

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[1]</sup>	177 <sup>[2]</sup>		
Units: Score on the scale				
arithmetic mean (standard deviation)				
Change at week 24 (n=162, 157)	-3.16 (± 7.72)	-2.87 (± 8.39)		

Notes:

[1] - FAS

[2] - FAS

### Statistical analyses

Statistical analysis title	P-3073 vs Vehicle difference
----------------------------	------------------------------

**Statistical analysis description:**

The linear effects model included the treatment group and the pooled site as dummy effects and the total NAPS1 Score at screening as continuous covariate.

Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7333
Method	Linear effects model
Parameter estimate	Adjusted mean difference
Point estimate	-0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.99
upper limit	1.4
Variability estimate	Standard error of the mean
Dispersion value	0.86

**Secondary: Nail Physician's Global Assessment (PGA) Response Rate at Week 24**

End point title	Nail Physician's Global Assessment (PGA) Response Rate at Week 24
-----------------	---

**End point description:**

Nail PGA score was used to assess the fingernail. For each affected fingernail, the proximal nail matrix, the distal nail matrix, and the nail bed were scored as 0-clear, 1-almost clear, 2-mild, 3-moderate or 4-severe. A responder fingernail was defined as a score of "clear" (0) or "almost clear" (1) and at least 2 points improvement from the baseline score. Nail PGA response rate is the proportion of subjects mild to moderate fingernails with nail PGA response which is the ratio of "number of subjects mild to moderate responder fingernails" by "number of affected mild to moderate fingernails at baseline" for each subject. "n" signifies subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Week 24

<b>End point values</b>	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[3]</sup>	177 <sup>[4]</sup>		
Units: Ratio of subject's responder fingernails				
arithmetic mean (standard deviation)				
Response rate at Week 24 (n=162, 157)	0.26 (± 0.31)	0.29 (± 0.32)		

**Notes:**

[3] - FAS

[4] - FAS

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
-----------------------------------	------------------------



**Statistical analysis description:**

A generalized linear mixed effects model for repeated measures (MMRM) was modelled to obtain an estimate of the probability to achieve a PGA response after 24 weeks of treatment. Only subjects with at least one mild to moderate fingernail were considered.

Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.7913
Method	MMRM Model
Parameter estimate	Median difference (net)
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.06

### Secondary: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Matrix Score at Week 24

End point title	Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Matrix Score at Week 24
-----------------	---

**End point description:**

NAPSI was used to assess nail psoriasis. The nail was assessed for nail matrix psoriasis in each quadrant of the nail. Nail matrix psoriasis was assessed by the presence of any features including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail. The score was 0 if the findings were not present, 1 if they were present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail had a matrix score (0-4). The number of mild to moderate psoriatic fingernails analysed at the baseline visit were 1165 and 1166 for the reporting groups P-3073 and Vehicle respectively. "n" signifies nails of subjects which were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline, Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[5]</sup>	177 <sup>[6]</sup>		
Units: Score on the scale				
arithmetic mean (standard deviation)				
Change at Week 24 (n= 1038, 1040)	-0.24 (± 1.21)	-0.26 (± 1.22)		

**Notes:**

[5] - FAS

[6] - FAS

**Statistical analyses**

Statistical analysis title	Statistical Analysis 1
Comparison groups	P-3073 v Vehicle

Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.382
Method	MMRM Model
Parameter estimate	Adjusted mean difference
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.14

## Secondary: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Bed Score at Week 24

End point title	Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Bed Score at Week 24
-----------------	--

End point description:

NAPSI was used to assess nail psoriasis. The nail was assessed for nail bed psoriasis in each quadrant of the nail. Nail bed psoriasis was assessed by the presence of any features including onycholysis, oil drop (salmon patch) dyschromia, splinter hemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. The score was 0 if the findings were not present, 1 if they were present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail had a nail bed score (0-4). The improvement in NAPSI Bed Score was defined as the achievement of a value of NAPSI Bed Score equal to zero (i.e. completely clearance of psoriatic signs). The number of mild to moderate psoriatic fingernails analysed at the baseline visit were 1165 and 1166 for the reporting groups P-3073 and Vehicle respectively. "n" signifies nails of subjects which were evaluable for this measure at given time for each group

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[7]</sup>	177 <sup>[8]</sup>		
Units: Score on the scale				
arithmetic mean (standard deviation)				
Change at Week 24 ( n= 1038, 1040)	-0.24 (± 1.04)	-0.17 (± 1.10)		

Notes:

[7] - FAS

[8] - FAS

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	P-3073 v Vehicle

Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0668
Method	MMRM Model
Parameter estimate	Adjusted mean difference
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.01

### Secondary: Change from Baseline in Subject's Quality-Of-Life as Assessed by Dermatology Life Quality Index (DLQI) at Week 24

End point title	Change from Baseline in Subject's Quality-Of-Life as Assessed by Dermatology Life Quality Index (DLQI) at Week 24
-----------------	---

End point description:

Dermatology Life Quality Index (DLQI) score was used to evaluate the impact of nail psoriasis on subject's quality-of-life. The DLQI Total score range from 0 (no effect) to 30 (extremely affected). The higher the score, the more quality of life is impaired. "n" signifies those subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[9]</sup>	177 <sup>[10]</sup>		
Units: Score on the scale				
arithmetic mean (standard deviation)				
Change at week 24, n=162, 157	-2.52 (± 5.54)	-2.64 (± 5.41)		

Notes:

[9] - FAS

[10] - FAS

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

The linear mixed effects model for repeated measures included treatment, pooled site, visit and treatment-by-visit interaction as fixed effects and baseline value as covariate. The unstructured variance-covariance matrix was used to take into account correlation among repeated measures within subject.

Comparison groups	P-3073 v Vehicle
-------------------	------------------

Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.7885
Method	MMRM Model
Parameter estimate	Adjusted mean difference
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.88
upper limit	1.16

## Secondary: Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Score at Week 24

End point title	Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Score at Week 24
-----------------	---

End point description:

NAPSI was used to assess nail psoriasis. The nail was assessed for nail matrix and bed psoriasis in each quadrant of the nail. Each nail was given a score for nail bed psoriasis (0-4) and nail matrix psoriasis (0-4) depending on the presence of any features of nail psoriasis in that quadrant. The score was 0 if no findings, and 4 if findings in 4 quadrants of a nail. The total nail score was the sum of those two (0-8). The sum of the scores from all involved fingernails was 0-80 (total NAPSI score for that subject at that time). The improvement in NAPSI score was defined as the achievement of a value of NAPSI score equal to zero. Proportion of subjects' mild to moderate fingernails with improvement in NAPSI Score is the ratio of "number of improved mild to moderate fingernails in NAPSI Score" by "number of affected mild to moderate fingernails at baseline" for each subject. "n" signifies the subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
End point timeframe:	
Week 24	

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[11]</sup>	177 <sup>[12]</sup>		
Units: Ratio of subject's improved fingernails				
arithmetic mean (standard deviation)				
Week 24 (n=162, 158)	0.20 (± 0.28)	0.22 (± 0.30)		

Notes:

[11] - FAS

[12] - FAS

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

A generalized linear mixed effects model was modelled to obtain estimate of the probability to achieve an improvement after 24 weeks of treatment. Only subjects with at least one mild to moderate

fingernail were considered.

Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.7434
Method	MMRM Model
Parameter estimate	Adjusted mean difference
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.05

### Secondary: Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Matrix Score at Week 24

End point title	Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Matrix Score at Week 24
-----------------	--

End point description:

NAPSI was used to assess each nail psoriasis. The nail was assessed for nail matrix psoriasis in each quadrant of the nail. Nail matrix psoriasis was assessed by the presence of any features including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail. Each nail had a nail matrix score of 0-4 where 0 if no findings, and 4 if findings in 4 quadrants of a nail. The improvement in NAPSI matrix score was defined as the achievement of a value of NAPSI matrix score equal to zero (i.e. completely clearance of psoriatic signs). Proportion of subjects' mild to moderate fingernails with improvement in NAPSI matrix Score is the ratio of "number of improved mild to moderate fingernails in NAPSI matrix Score" by "number of affected mild to moderate fingernails at baseline" for each subject. "n" signifies the subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[13]</sup>	177 <sup>[14]</sup>		
Units: Ratio of subject's improved fingernails				
arithmetic mean (standard deviation)				
Week 24 (n=162, 158)	0.28 (± 0.32)	0.28 (± 0.32)		

Notes:

[13] - FAS

[14] - FAS

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

**Statistical analysis description:**

A generalized linear mixed effects model was modelled to obtain estimate of the probability to achieve an improvement after 24 weeks of treatment. Only subjects with at least one mild to moderate fingernail were considered.

Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9753
Method	Linear mixed effects model
Parameter estimate	adjusted mean difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.07

### Secondary: Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Bed Score at Week 24

End point title	Proportion of Subject's Mild to Moderate Fingernails With Improvement in Nail Psoriasis Severity Index (NAPSI) Bed Score at Week 24
-----------------	---

**End point description:**

NAPSI was used to assess each nail psoriasis. The nail was assessed for nail bed psoriasis in each quadrant of the nail. Nail bed psoriasis was assessed by the presence of any features including onycholysis, oil drop (salmon patch) dyschromia, splinter hemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. Each nail had a nail bed score of 0-4 where 0 if no findings, and 4 if findings in 4 quadrants of a nail. The improvement in NAPSI Bed Score was defined as the achievement of a value of NAPSI Bed Score equal to zero (i.e. completely clearance of psoriatic signs). Proportion of subjects' mild to moderate fingernails with improvement in NAPSI Bed Score is the ratio of "number of improved mild to moderate fingernails in NAPSI Bed Score" by "number of affected mild to moderate fingernails at baseline" for each subject. "n" signifies the subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[15]</sup>	177 <sup>[16]</sup>		
Units: Ratio of subject's improved fingernails				
arithmetic mean (standard deviation)				
Week 24 (n=162, 158)	0.16 (± 0.24)	0.18 (± 0.26)		

**Notes:**

[15] - FAS

[16] - FAS

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
A generalized linear mixed effects model was modelled to obtain estimate of the probability to achieve an improvement after 24 weeks of treatment. Only subjects with at least one mild to moderate fingernail were considered.	
Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9988
Method	Linear mixed effects model
Parameter estimate	Adjusted mean difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.05

## Secondary: Subject Acceptance of Study Therapy at Week 24

End point title	Subject Acceptance of Study Therapy at Week 24
End point description:	
The subjects' acceptability of the study therapy was evaluated on the 4-point scale ranged from 1 = poor (very unpleasant and unsatisfactory), 2 = moderate (not fully satisfactory), 3 = good (satisfactory) to 4 = very good (fully satisfactory). "N" signifies those subjects who were evaluable for this measure for each group.	
End point type	Secondary
End point timeframe:	
Week 24	

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	171 <sup>[17]</sup>	167 <sup>[18]</sup>		
Units: Subject				
Poor	26	20		
Moderate	34	41		
Good	64	63		
Very Good	39	39		
Not Evaluated	8	4		

Notes:

[17] - FAS subjects evaluable for this end point.

[18] - FAS subjects evaluable for this end point.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change in Discomfort Due to Fingernail Psoriasis as Measured on a Visual Analogue Scale (VAS) at Week 24

End point title	Change in Discomfort Due to Fingernail Psoriasis as Measured on a Visual Analogue Scale (VAS) at Week 24
-----------------	--

End point description:

The VAS was used to measure the amount of discomfort felt by the subject in fingernail; it ranges from no discomfort (0) to worst possible discomfort (100). "n" signifies those subjects who were evaluable for this measure at given time point for each group.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	P-3073	Vehicle		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	181 <sup>[19]</sup>	177 <sup>[20]</sup>		
Units: Score on a scale				
arithmetic mean (standard deviation)				
Change at Week 24, n=156, 157	-12.63 (± 24.95)	-11.25 (± 27.45)		

Notes:

[19] - FAS

[20] - FAS

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

The linear mixed effects model for repeated measures included treatment, pooled site, visit and treatment-by-visit interaction as fixed effects and baseline value as covariate. The unstructured variance-covariance matrix was used to take into account correlation among repeated measures within subjects.

Comparison groups	P-3073 v Vehicle
Number of subjects included in analysis	358
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.78
Method	MMRM Model
Parameter estimate	Adjusted mean difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.63
upper limit	4.23



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From start of study drug application until follow up (Week 28)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	P-3073
-----------------------	--------

Reporting group description:

Subjects with mild to moderate psoriatic fingernail/s, were treated with P-3073 nail solution as a topical application once daily for 24 weeks.

Reporting group title	Vehicle
-----------------------	---------

Reporting group description:

Subjects with mild to moderate psoriatic fingernail/s, were treated with vehicle solution matched to P-3073 nail solution as a topical application once daily for 24 weeks.

Serious adverse events	P-3073	Vehicle	
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 176 (5.68%)	4 / 176 (2.27%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Limb traumatic amputation			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nail injury			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Syncope			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	2 / 176 (1.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			

Psoriasis alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	3 / 176 (1.70%) 0 / 3 0 / 0	0 / 176 (0.00%) 0 / 0 0 / 0	
Renal and urinary disorders Renal colic alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 176 (0.57%) 0 / 1 0 / 0	0 / 176 (0.00%) 0 / 0 0 / 0	
Musculoskeletal and connective tissue disorders Muscular weakness alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 176 (0.00%) 0 / 0 0 / 0	1 / 176 (0.57%) 0 / 1 0 / 0	
Psoriatic arthropathy alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 176 (0.57%) 0 / 1 0 / 0	0 / 176 (0.00%) 0 / 0 0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	P-3073	Vehicle	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	105 / 176 (59.66%)	91 / 176 (51.70%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Skin papilloma			

alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Vascular disorders Hypertension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 2	2 / 176 (1.14%) 2	
Arteriosclerosis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Hypotension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	1 / 176 (0.57%) 1	
Surgical and medical procedures Atherosclerosis prophylaxis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Tooth extraction alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	4 / 176 (2.27%) 4	0 / 176 (0.00%) 0	
Cataract operation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Wisdom teeth removal alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Sebaceous cyst excision alternative assessment type: Non-systematic			

subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
General disorders and administration site conditions			
Peripheral swelling alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 5	
Fatigue alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	1 / 176 (0.57%) 1	
Pyrexia alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	3 / 176 (1.70%) 9	
Immune system disorders			
Allergy to arthropod bite alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Allergy to arthropod sting alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Sarcoidosis alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Hypersensitivity alternative assessment type: Non- systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 2	0 / 176 (0.00%) 0	
Reproductive system and breast disorders			

Dysmenorrhoea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 2	
Menstrual disorder alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Oligomenorrhoea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Rhinorrhoea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	1 / 176 (0.57%) 1	
Oropharyngeal pain alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	4 / 176 (2.27%) 4	2 / 176 (1.14%) 2	
Cough alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	6 / 176 (3.41%) 8	1 / 176 (0.57%) 1	
Psychiatric disorders Anxiety alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Depression alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Insomnia			

alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Stress alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 2	0 / 176 (0.00%) 0	
Sleep disorder alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Investigations Blood cholesterol increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Aspartate aminotransferase increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 2	3 / 176 (1.70%) 3	
Blood bilirubin increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Alanine aminotransferase increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 2	2 / 176 (1.14%) 2	
Blood glucose increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 4	1 / 176 (0.57%) 1	
Blood glucose abnormal alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Blood pressure increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Blood triglycerides increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 176 (1.70%)	2 / 176 (1.14%)
occurrences (all)	3	3
Blood potassium increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	1 / 176 (0.57%)
occurrences (all)	2	1
Gamma-glutamyltransferase increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 176 (1.70%)	0 / 176 (0.00%)
occurrences (all)	4	0
Glucose urine present		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	2	0
Transaminases increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Liver function test abnormal		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	2 / 176 (1.14%)
occurrences (all)	2	2
Liver function test increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1



Injury, poisoning and procedural complications			
Arthropod bite			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Contusion			
alternative assessment type: Non-systematic			
subjects affected / exposed	3 / 176 (1.70%)	4 / 176 (2.27%)	
occurrences (all)	3	6	
Injury corneal			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Fall			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Eye injury			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Limb injury			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 176 (1.14%)	1 / 176 (0.57%)	
occurrences (all)	2	1	
Nail injury			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Laceration			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Road traffic accident			
alternative assessment type: Non-			

systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Skin injury			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	1 / 176 (0.57%)	
occurrences (all)	1	1	
Traumatic haematoma			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Wound			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Congenital, familial and genetic disorders			
Type V hyperlipidaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Cardiac disorders			
Angina pectoris			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Nervous system disorders			
Dizziness			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Headache			
alternative assessment type: Non-systematic			
subjects affected / exposed	31 / 176 (17.61%)	27 / 176 (15.34%)	
occurrences (all)	89	56	
Cervical radiculopathy			

alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Hypoaesthesia			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Intercostal neuralgia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Tremor			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Syncope			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Migraine			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Ear pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Middle ear inflammation			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Eye disorders			

Cataract alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%)	1 / 176 (0.57%)	
	0	1	
Chalazion alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%)	0 / 176 (0.00%)	
	1	0	
Conjunctival hyperaemia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%)	0 / 176 (0.00%)	
	1	0	
Visual acuity reduced alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%)	0 / 176 (0.00%)	
	1	0	
Gastrointestinal disorders			
Abdominal distension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%)	1 / 176 (0.57%)	
	0	1	
Abdominal pain upper alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	3 / 176 (1.70%)	3 / 176 (1.70%)	
	13	3	
Abdominal pain alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%)	0 / 176 (0.00%)	
	1	0	
Aphthous ulcer alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%)	0 / 176 (0.00%)	
	2	0	
Diarrhoea alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 176 (0.57%)	4 / 176 (2.27%)	
occurrences (all)	1	4	
Dyspepsia			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 176 (1.14%)	1 / 176 (0.57%)	
occurrences (all)	3	1	
Gastrointestinal disorder			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Gastrooesophageal reflux disease			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Nausea			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Toothache			
alternative assessment type: Non-systematic			
subjects affected / exposed	4 / 176 (2.27%)	3 / 176 (1.70%)	
occurrences (all)	4	6	
Skin and subcutaneous tissue disorders			
Dermatitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Dermatitis allergic			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Eczema			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 176 (0.57%)	2 / 176 (1.14%)
occurrences (all)	1	2
Hyperkeratosis		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Erythema		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	0 / 176 (0.00%)
occurrences (all)	2	0
Onychalgia		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Nail disorder		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	2 / 176 (1.14%)
occurrences (all)	2	3
Pruritus		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	2	0
Onychoclasia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	3	0
Psoriasis		
alternative assessment type: Non-systematic		
subjects affected / exposed	8 / 176 (4.55%)	6 / 176 (3.41%)
occurrences (all)	10	8
Skin disorder		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	2 / 176 (1.14%)
occurrences (all)	0	2

Rebound psoriasis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Skin ulcer alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Skin irritation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	18 / 176 (10.23%) 51	13 / 176 (7.39%) 32	
Solar dermatitis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	0 / 176 (0.00%) 0	
Swelling face alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	1 / 176 (0.57%) 1	
Renal and urinary disorders Cystitis noninfective alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 176 (0.00%) 0	1 / 176 (0.57%) 1	
Renal colic alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 176 (1.14%) 3	1 / 176 (0.57%) 1	
Haematuria alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 176 (0.57%) 1	1 / 176 (0.57%) 1	
Renal cyst alternative assessment type: Non-systematic			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Proteinuria</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Urinary tract inflammation</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 176 (0.00%)</p> <p>0</p> <p>1 / 176 (0.57%)</p> <p>1</p> <p>0 / 176 (0.00%)</p> <p>0</p> <p>1 / 176 (0.57%)</p> <p>1</p>	<p>1 / 176 (0.57%)</p> <p>1</p> <p>0 / 176 (0.00%)</p> <p>0</p> <p>1 / 176 (0.57%)</p> <p>1</p>	
<p>Endocrine disorders</p> <p>Hypothyroidism</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 176 (1.14%)</p> <p>2</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Arthritis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Back pain</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Muscle spasms</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Joint swelling</p> <p>alternative assessment type: Non-systematic</p>	<p>3 / 176 (1.70%)</p> <p>6</p> <p>2 / 176 (1.14%)</p> <p>2</p> <p>7 / 176 (3.98%)</p> <p>9</p> <p>1 / 176 (0.57%)</p> <p>1</p>	<p>4 / 176 (2.27%)</p> <p>4</p> <p>0 / 176 (0.00%)</p> <p>0</p> <p>9 / 176 (5.11%)</p> <p>19</p> <p>0 / 176 (0.00%)</p> <p>0</p>	



subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Musculoskeletal pain		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	2 / 176 (1.14%)
occurrences (all)	1	2
Intervertebral disc protrusion		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Pain in extremity		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Musculoskeletal chest pain		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Myalgia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	2 / 176 (1.14%)
occurrences (all)	2	2
Psoriatic arthropathy		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Neck pain		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	3
Spinal pain		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 176 (1.70%)	1 / 176 (0.57%)
occurrences (all)	4	1

<p>Infections and infestations</p> <p>Conjunctivitis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Bronchitis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 176 (2.27%)</p> <p>4</p>	<p>2 / 176 (1.14%)</p> <p>2</p>	
<p>Bronchitis bacterial</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Cystitis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	
<p>Ear infection</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Folliculitis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>3</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	
<p>Gastroenteritis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 176 (1.70%)</p> <p>4</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Gingivitis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 176 (0.57%)</p> <p>1</p>	<p>0 / 176 (0.00%)</p> <p>0</p>	
<p>Gastroenteritis viral</p> <p>alternative assessment type: Non-systematic</p>			

subjects affected / exposed	1 / 176 (0.57%)	1 / 176 (0.57%)
occurrences (all)	1	1
Hordeolum		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Gastrointestinal infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	1 / 176 (0.57%)
occurrences (all)	2	1
Infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Herpes zoster		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Influenza		
alternative assessment type: Non-systematic		
subjects affected / exposed	6 / 176 (3.41%)	5 / 176 (2.84%)
occurrences (all)	6	5
Paronychia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	19 / 176 (10.80%)	11 / 176 (6.25%)
occurrences (all)	22	14
Pharyngitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	4 / 176 (2.27%)	0 / 176 (0.00%)
occurrences (all)	4	0

Pulpitis dental		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	0 / 176 (0.00%)
occurrences (all)	2	0
Sinusitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Rhinitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	4 / 176 (2.27%)	4 / 176 (2.27%)
occurrences (all)	4	4
Skin infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	2
Tinea versicolour		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)
occurrences (all)	0	1
Urinary tract infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 176 (1.14%)	2 / 176 (1.14%)
occurrences (all)	2	3
Upper respiratory tract infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Tonsillitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)
occurrences (all)	1	0
Vaginal infection		
alternative assessment type: Non-systematic		

subjects affected / exposed	1 / 176 (0.57%)	1 / 176 (0.57%)	
occurrences (all)	1	1	
Viral infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 176 (1.14%)	1 / 176 (0.57%)	
occurrences (all)	2	1	
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 176 (0.57%)	1 / 176 (0.57%)	
occurrences (all)	1	1	
Hypercholesterolaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	4 / 176 (2.27%)	3 / 176 (1.70%)	
occurrences (all)	4	3	
Diabetes mellitus			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 176 (1.14%)	0 / 176 (0.00%)	
occurrences (all)	2	0	
Gout			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	1	
Hyperglycaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 176 (0.00%)	1 / 176 (0.57%)	
occurrences (all)	0	2	
Hyperuricaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 176 (1.14%)	0 / 176 (0.00%)	
occurrences (all)	2	0	
Hyperlipidaemia			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 176 (0.57%)	0 / 176 (0.00%)	
occurrences (all)	1	0	
Hypertriglyceridaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	4 / 176 (2.27%)	4 / 176 (2.27%)	
occurrences (all)	4	4	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 March 2016	<ul style="list-style-type: none"><li>- 'Subjects acceptance of study therapy at week 24' was added as secondary endpoint.</li><li>- Definition of the secondary endpoint related to Nail PGA response was updated.</li><li>- Rewording of the exclusion criteria related to the use of concomitant topical and systemic psoriatic treatments.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported